Skip to main content
Pelthos Therapeutics Inc. logo

Pelthos Therapeutics Inc. — Investor Relations & Filings

Ticker · PTHS ISIN · US1711261057 US Manufacturing
Open in API
Filings indexed 205 across all filing types
Latest filing 2024-11-13 Interim / Quarterly Rep…
Country US United States of America
Listing US PTHS

About Pelthos Therapeutics Inc.

https://ir.pelthos.com/

Pelthos Therapeutics Inc. is a biopharmaceutical company focused on commercializing innovative therapeutic products for patients with unmet medical needs. Its lead product is ZELSUVMI™ (berdazimer topical gel, 10.3%), the first FDA-approved, at-home prescription treatment for molluscum contagiosum. ZELSUVMI is based on the company's proprietary nitric oxide-releasing technology platform, NITRICIL™, which is also being utilized for a pipeline of other product candidates. The company's portfolio also includes the acquired asset Xepi (ozenoxacin) Cream, 1%.

Recent filings

Filing Released Lang Actions
424B3
Interim / Quarterly Report Classification · 100% confidence The document is a Form 10-Q quarterly report filed with the SEC for the quarter ended September 30, 2024. It contains detailed unaudited financial statements including balance sheets, statements of operations, changes in stockholders' deficit, and cash flows, as well as management's discussion and analysis, risk factors, and other required disclosures. The presence of comprehensive financial data and analysis for a quarterly period clearly identifies this as an Interim / Quarterly Report. The document is not a brief announcement or a certification, but a full quarterly filing with substantive financial content.
2024-11-13 English
424B3
Interim / Quarterly Report Classification · 100% confidence The document is a Form 10-Q Quarterly Report filed with the SEC for the quarter ended September 30, 2024. It contains detailed unaudited financial statements including balance sheets, statements of operations, changes in stockholders' deficit, and cash flows, as well as management's discussion and analysis. The presence of comprehensive financial data and analysis for a quarterly period clearly identifies this as an Interim / Quarterly Report. The document is lengthy (15,000 characters) and contains substantive financial information, not merely an announcement or certification. Therefore, it fits the definition of an Interim / Quarterly Report (IR).
2024-11-13 English
10-Q
Interim / Quarterly Report Q3 2024
2024-11-13 English
SC 13G/A
Major Shareholding Notification
2024-11-13 English
8-K
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is a Form 8-K Current Report filed with the SEC by Chromocell Therapeutics Corporation. It reports the results of the 2024 Annual Meeting of Stockholders, including detailed voting results on multiple proposals, which is typical for a Declaration of Voting Results. Additionally, it announces an amendment to the company's stock repurchase plan, which relates to share repurchase activity. The primary focus, however, is on the voting results certified by the inspector of elections. The document is about the official results from shareholder votes at the Annual Meeting, which fits the category of Declaration of Voting Results & Voting Rights Announcements (DVA). The length of the document (7,930 characters) and the detailed voting tables confirm it is not a mere announcement of a report but the actual voting results. Therefore, the correct classification is DVA with high confidence.
2024-10-24 English
DEF 14A
Proxy Solicitation & Information Statement
2024-09-26 English

Browse filings by year

5 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.